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Introduction. Rapidly growing prevalence of cardiovascular disease is a major threat for the developed as well as developing
world warranting urgent need of intervention. Complementary and alternative medicines are gaining popularity among general
population because of their safety profile and easy administration. Garlic, in particular, is considered to be one of the best
disease-preventive foods because of its potent and widespread effects. This study was done to find out the role of garlic usage
in cardiovascular disease prevention.Methodology. Major databases including Google, PubMed, MEDLINE, and Cochrane library
view were used for the literature search. Clinical trials conducted on humans assessing role of garlic usage in cardiovascular disease
prevention and the possible mechanisms responsible for such therapeutic actions were assessed. Results. Various clinical trials and
meta-analyses conducted have shown positive impact of garlic in cardiovascular-disease prevention especially its effects on lipid
levels; however, some contradictory results are also reported. Similarly, its effects on hypertension control, and platelet are also
mild with limited data availability. The possible reason for these inconsistent results is the difference in preparations with diverse
composition, variations in sulphur content present in different garlic preparations used, and methodological variations in subject
recruitment, duration of study, dietary control and so forth.Conclusion. Garlic can be used as an adjuvant with lipid-lowering drugs
for control of lipids, however, its role as a main therapeutic agent cannot be recommended and it is suggested that more meta-
analyses using standardized preparations with a close watch on methodological shortfalls should be conducted to prove its role.
1. Introduction
The epidemic of cardiovascular disease is growing at an
alarming pace throughout the world [1]. It is recognized
as one of the leading causes of mortality worldwide caus-
ing more than 80% of deaths in low- and middle-income
countries [2]. Cardiovascular disease refers to spectrum of
illnesses that includes heart disease, vascular diseases of the
brain, kidney, and peripheral arterial disease [3]. According
to an estimate by World Health Organization, approximately
17.3 million people died from CVDs in 2008, representing
30% of all global deaths. Out of these deaths, 7.3 million
occurred secondary to coronary heart disease and 6.2 million
as a consequence of stroke [2]. It is anticipated that by 2020
cardiovascular diseases are predicted to be the major cause of
morbidity and mortality in most developing nations around
the globe [4]. Atherosclerosis and hypertension aremeasured
as the major risk factor along with smoking, obesity, and sed-
entary life styles leading to increasing trend of this major
threat [5].
Today, in this era of rapid advancement in medical tech-
nology, herbal or botanical preparations, commonly referred
to as complementary and alternate medicine (CAM),
approaches have gained lots of popularity in terms of health
care maintenance, and a large number of population in the
developing as well as developed world prefer to use (CAM)
as a source of curative and preventive remedy for various ill-
nesses [6, 7]. CAM is defined as a group of diverse medical
and health systems practices and products that are not
generally considered as part of conventional medicine [8].
According to 2007 National Health Interview Survey (NHIS)
report, approximately 38% of US adults and 12% of child-
ren are using CAM in the past 12 months; lifetime prevalence
of CAM use in the United States and worldwide has
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increased steadily since 1950 (9.10). Most common types
of CAM therapies used were natural products, such as fish
oil/omega 3, glucosamine, Echinacea, and flaxseed (17.7%),
deep breathing (12.7%), meditation (9.4%), chiropractic and
osteopathic (8.6%), and massage (8.3%), followed by yoga,
diet-based therapies, progressive relaxation, guided imagery,
and homeopathic treatment [9].
Among all these remedies, plants-based functional foods
have gained lots of recognition throughout the world and it
is believed that these natural substances have the potential to
reduce the detrimental effect of a number of cardiovascular
diseases and associated risk factors [10]. The probable reason
for this rising trend is skeptic approach of general public
towards conventional medicine due to fear of more side
effects and increasing cost.This fact was further driven by the
belief of increased safety profile and easy availability of plant-
based natural products in comparison to orthodox medicine.
Garlic has been used as a therapeutic agent for many illnesses
over centuries as evident from various studies; however, its
role in cardiovascular disease prevention is still questionable.
This review was done to find out the efficacy of garlic in
cardiovascular disease prevention through evidence-based
approach by analyzing clinical trials and systematic review in
the above mentioned area.
2. Garlic as a Potential Herb
Garlic (Allium sativum) has played an important dietary as
well as medicinal role in human history. The role of garlic
(Allium sativum) as a potential herb has been acknowledged
for over 5000 years. Garlic and its various preparations are
being readily consumed as a food and spice by various cul-
tures for centuries [11]. It was also documented as a choice of
medical therapy to combat many diseases among Egyptians
[12]. Similarly, it is also considered as an imperative part
of Indian traditional medicine, that is, Ayurveda, Tibbi and
Unani, and so forth. In addition, it is also claimed to pos-
sess beneficial effects for the prevention of various aspects
of cardiovascular disease including hypertension and dyslipi-
demia [13].
3. Garlic Composition
Garlic is available in many forms among these raw garlic and
aqueous extract preparation is used more frequently. Allicin
is the principal bioactive compound present in garlic and
primarily contains sulphur as a main constituent which on
break down gives garlic its characteristic odor. It is produced
as a result of activation of alliinase enzyme after crushing or
chopping of raw garlic.The enzyme Allinase is inactivated by
heat leaving behind alliin as the main constituent present in
the water extract of heat-treated garlic. The composition of
garlic powderwhich is produced after dehydration and crush-
ing is the same as raw garlic and alliinase activity is preserved;
however, caution needs to be taken regarding temperature
regulation as Allinase is inactivated if temperature exceeds
beyond 60∘C. Apart from Alliin, other important sulfur-
containing compounds present in garlic homogenate include
allyl methyl thiosulfonate, 1-propenyl allyl thiosulfonate, and
𝛾-L-glutamyl-S-alkyl-L-cysteine. On an average, a garlic bulb
contains up to 0.9% g-glutamylcysteines and up to 1.8% alliin
[14].
4. AGE Preparation
Another important and extensively studied garlic preparation
is aged garlic extract (AGE).This form is produced by storage
of sliced rawgarlic in 15–20%ethanol for 20months.This pro-
cess of storage leads to alteration in composition of the garlic
extract, the odorous, harsh, and irritating compounds in
garlic are converted naturally into stable and safe sulfur com-
pounds with substantial loss of allicin activity and increased
activity of new compounds, like S-allylcysteine (SAC), S-
allylmercaptocysteine, and allixin [15]. SAC can be used for
standardization because of its bioavailability property.
5. Garlic Oil
Garlic oil another important preparation is produced as a
result of distillation process of raw garlic. Garlic essential oil
is obtained by steam distillation of garlic. The essential oil
content of garlic cloves is 0.2–0.5% and consists of a variety
of sulfides, such as diallyl disulphide (DADS) and diallyl
trisulfide (DATS) [16, 17]. All the water soluble contents
including allicin are completely eliminated from the oil. Oil
macerates were originally developed for use as condiments.
Oil macerate products are made of encapsulated mixtures of
whole garlic cloves ground into vegetable oil.This preparation
contains allicin-decomposed compounds such as dithiins,
ajoene and sulfides, residual amounts of alliin, and other
constituents in garlic [16].
6. Garlic Powder
Garlic powder is primarily used as a flavoring agent for con-
diments and processed foods. Garlic cloves are sliced or
crushed, dried, and ground into powder. The composition of
garlic powder is the same as that of raw garlic; however, the
proportions and amounts of various constituents differ sig-
nificantly; that is, average content of alliin present in garlic is
0.8% however, raw garlic contains around 3.7mg/gm of alliin
[18].
7. Garlic and Cardiovascular
Disease Prevention
Cardiovascular disease is one of the leading cause of morbid-
ity and mortality worldwide. Role of garlic in cardiovascular
disease prevention has been a topic of concerns for many
years. Various observational and experimental studies done
on animals showed encouraging results. However, these
claimed benefits were not supported by evidence-based clin-
ical studies. This fact prompted many researchers to conduct
clinical trials in order to explore and address the efficacy and
association of garlic with various aspects of cardiovascular
disease.
In recent years, garlic has been a focus of attention
because of its potential role in the prevention of various
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aspects of cardiovascular disease [19, 20]. Evidence from
numerous studies suggests that garlic works through various
mechanisms to achieve this favorable effect including reduc-
tion of serum lipids and blood pressure levels, inhibition of
platelet aggregation, and increasing fibrinolytic antioxidant
activity. Majority of the studies reported have shown positive
impact; however, few numbers of contradictory studies have
[21, 22] made the role of garlic questionable especially with
regards to its effects on lipid levels and hypertension. This
review will critically examine the current scientific literature
concerning claims of cardiovascular benefits from regular
consumption of garlic or its preparations and the possible
mechanisms responsible for such therapeutic actions.
8. Methodology
This paper is based on a literature search of clinical trials
and systematic reviews published from 1990–2012 to see the
effect of Garlic on cardiovascular disease prevention. For
this purpose multiple search engines including MEDLINE,
PubMed, Google, and Cochrane library were used. Search
was validated by other author.
9. Inclusion Criteria
All human studies (clinical trials) in English assessing the
effect of garlic on cardiovascular disease prevention among
patients with dyslipidemia, hypertension, or cardiovascular
disease were included.
10. Exclusion Criteria
Studies conducted among animalswere excluded.Theses, dis-
sertations, unpublished data, and letter to editor were also ex-
cluded.
A number of keywords were used for data searching
including garlic and cardiovascular disease clinical trial,
garlic hypertension and dyslipidemia, platelet aggregation,
and clinical trial.
11. Garlic Role in Dyslipidemia
Dyslipidemia is documented as a major risk factor respon-
sible for the development of atherosclerosis and cardiovas-
cular disease [23]. Lipid abnormalities include high LDL-
C (low-density lipoprotein cholesterol), high triglycerides
and low HDL-C (high-density lipoproteins cholesterol) lev-
els. Cholesterol present in 𝛽-lipoprotein (LDL) and pre-B-
lipoprotein gets deposited into the blood vessels, while 𝛼-
lipoprotein (HDL) helps to reduce serum cholesterol [24].
Impact of garlic on elevated lipid level is themost widely stud-
ied outcome of interest as evident from Table 1. Considerable
evidence from the literature supports the invaluable role of
garlic in the treatment of hypercholesterolemia through inhi-
bition of cholestrol biosynthesis in the liver and also by inhi-
bition of oxidation of low-density lipoproteins [25]. Dietary
approach is the initial step in the management of dyslipi-
demia, andmany people with dyslipidemia are using garlic as
an alternative medicine to normalize their raised lipid levels.
A number of randomized, controlled trials were carried
out to see the effect of different preparation of garlic on lipid
levels. In the early 1980s, a trial done [19] on human sub-
ject after ingestion of 40 gm garlic demonstrated significant
reduction in total cholestrol and triglyceride levels. Similarly,
one study conducted by Mader [20] in 1990 among patients
suffering from dyslipidemia over a period of 16 weeks using
800mg of garlic (standardized to 1.3% of Alliin) showed
12% reduction in serum cholestrol levels and 17% reduction
in triglyceride levels in comparison to placebo; however, it
was also noticed that the greatest cholesterol-lowering effects
were seen in patients with initial total cholesterol values
between 250 and 300mg/dL. The results of this trial were
somewhat contradicted by findings of a trial by Saradeth et
al. [26] where 600mg of dried garlic powder (Kwai, Lichwer
standardized to 1.3% alliin) was given to healthy patients with
normal lipid levels over a period of 10 weeks. There was
a significant reduction in total cholestrol and triglycerides
levels confirming the fact that it can induce changes in
blood lipids, even if these variables had been normal to
start with Similarly another trial by Gadkari and Joshi on
healthy medical students after consumption of 10 gm raw
garlic showed significant reduction in serum cholesterol and
increase in clotting time and fibrinolytic activity [27].
Clinical trials using different types of garlic preparations
in hypercholesterolemia patients have demonstrated debat-
able results, and it was assumed that these discrepancies may
have resulted due to the differences of the composition of
garlic preparations and the response they may induce. This
fact was well proven by a study done by Sobenin et al. [28]
in which patients with mildly raised lipid levels were given
garlic powder tablets (allicor) containing 600mg of garlic
content. A moderate decrease in lipid levels was seen (7.6%
decrease in cholesterol; 11.7% decrease in LDL levels); in addi-
tion, a substantial rise in HDL level 11.5% was also noticed. It
was assumed that this hypocholesterolemic action of garlic
preparations may be due to the use of a time-released form
of garlic powder tablets. Similarly, a commonly used prepa-
ration of garlic in the form of AGE extract of 7.2 gm daily for
6 months also showed beneficial effects on the lipid profile
of moderately hypercholesterolemia subjects. There was an
overall 6.1% decrease in cholestrol levels and 4% decrease in
LDL levels noticed thus confirming its efficacy [29].
Another randomized placebo control trial using 5 gm of
raw garlic on patients with mildly raised lipids was used for
42 days and demonstrated significant reduction in cholestrol
and triglyceride levels with a rise in HDL levels; however,
these effects were not sustainable and returned to baseline
levels as soon as the garlic use was withdrawn.This suggested
that garlic consumption alone can decrease serum lipids in
patients with mildly raised lipid levels; however, it cannot be
used as the main therapeutic agent for hyperlipidemia [30].
Dyslipidemia refers to increase in cholestrol, triglyc-
erides, and LDL levels with a decrease in HDL level (below
40mg). It was expected that apart from decreasing cholestrol,
LDL and triglycerides levels, garlic also has an impact on
low HDL which was further established by a trial conducted
on healthy individuals with a decreased HDL levels below
10mg at baseline. They were given high-fat diet followed
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Table 1: Effects of garlic on lipid levels.
Study Type Target Durationof Rx Dose Case/control Outcome
Mader, (1990) [20]
Randomized,
placebo-controlled
trial
Hyperlipidemic 12 weeks 800mg garlicpowder 130/131
Dec in T. chol level—12%,
TG level—17%
Gadkari and Joshi,
(1991) [27]
Randomized
control trial Normal individuals 2 months
10 gm of raw
garlic 25/25
Dec T. chol, increase
clotting time, and
fibrinolytic activity
Rotzsch et al.,
(1992) [31]
Randomized,
placebo-controlled,
double-blind trial
Healthy
individuals with
low HDL
6 weeks 900mg garlicpowder 12/12
Dec TG levels and increase
HDL levels
Saradeth et al.,
(1994) [26]
Randomized
double-blind study,
placebo-controlled
trial
Healthy
individuals with
normal lipid levels
15 weeks 600mg driedgarlic powder 34/34
T. chol dec from 223 to
214mg/dL
TG dec from 124 to
118mg/dL
Steiner et al.,
(1996) [29]
Double-blind
crossover trial Hyperlipidemic 11 months 7.2 g aged garlic 20/21
Dec T. chol 6.1%, dec LDL
4%, systolic BP 5.5% dec,
and modest dec in diastolic
Bp noticed
Isaacsohn et al.,
(1998) [38]
Randomized,
double-blind,
placebo-control
trial
Hyperlipidemic 12 weeks 900mg garlicpowder (Kwai) 28/22
No change in lipid levels
noticed
Berthold et al.,
(1998) [39]
Double-blind,
randomized,
placebo-controlled
trial
Hyperlipidemic 12 weeks 10mg garlic oil 12/13 No change in lipids orlipoproteins levels noticed
Satitvipawee et al.,
(2003) [37]
Randomized,
double-blind,
placebo-controlled
trial
Hyperlipidemic 4 weeks/12weeks Garlic extract 70/76
No dec in T. chol, DL, TG,
and HDL levels noticed
Mahmoodi et al.,
(2006) [30] Clinical trial Hyperlipidemic 42 days
Raw garlic 5 gm
twice daily 30
Dec T. chol, dec LDL, dec
TG, increase HDL level
Reversed after stopping of
garlic
Sobenin et al.,
(2008) [28]
Double blinded
placebo controlled Hyperlipidemic 12 weeks
Allicor
(600mg daily) 21/21
T. chol 7.6% dec, LDL 11.8%,
and HDL inc 11.5%
T. chol: total cholesterol, HDL: high-density lipoprotein, TG: triglyceride, LDL: low-density lipoprotein, and VLDL: very low-density lipoprotein.
by garlic powder preparation (Sapec, Kwai) of 900mg daily
for 6 weeks. A significant decrease in triglyceride levels was
observed in the treatment group in comparison to placebo
group with a significant rise in HDL levels above baseline
[31]. Similarly another study reported that 3 g of fresh garlic
(1 clove) daily for 16 weeks had a 21% decrease in cholesterol
levels [32].
Despite the existence of various clinical trials, the role of
garlic in treating dyslipidemia is still debatable. In order to
address this query a various meta-analyses were also con-
ducted. A meta-analyses done by Silagy and Neil studied 16
trials among 952 patients using garlic, both in powder and
nonpowder form. There was an overall reduction in cho-
lestrol level seen that is, 8% with powdered form while
15% with nonpowder preparations. Significant lowering of
serum triglyceride was also noticed, while HDL level remains
unchanged [33].
Similarly, another meta-analyses by Warshafsky et al.
among patients with cholestrol levels greater than 200mg
showed significant reduction in total cholesterol levels. It was
suggested that garlic in an amount approximately one half to
one clove per day is effective in reducing cholesterol levels by
about 9% [34].
A recent meta-analyses conducted by Zeng et al. in 2012
clearly illustrated that garlic therapy is more effective if used
for a long term with higher baseline total cholestrol levels;
they also concluded that garlic powder and aged garlic extract
were more effective in reducing serum TC levels, while garlic
oil was more effective in lowering serum TG levels [35]. A
trial comparing garlic with a commercial lipid-lowering drug
(bezafibrate) found them to be equally effective in decreasing
lipids to a statistically significant extent [36].
There were few clinical trials which did not show any
effects on lipid levels. A trial done by Satitvipawee et al. for
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Table 2: Effect of garlic on blood pressure levels.
Study Type Target Duration of Rx Dose Case/control Outcome
Zhang et al.,
(2001) [48]
Parallel-controlled
trial Hypertensives 16 weeks
Distilled garlic oil
12.3mg/d 14/13 Garlic oil lowers SBP and DBP
Dhawan and Jain,
(2004) [49]
Not placebo
controlled Hypertensives 2 months
Garlic pearls
250mg 20/20
Dec Bp, dec ox-LDL, and
8-iso-PGF2alpha levels
Capraz et al.,
(2007) [55]
Randomized
placebo control
trial
Hypertensives 70 minutes Rw garlic, Garlictablets 25/25/25 No effects on BP levels
Duda et al.,
(2008) [51]
Prospective and
uncontrolled
clinical study
Hypertensives 30 days
Antihypertensive
drug + Garlic
capsules
38/32 Dec total lipids and lipidperoxidation noticed
Ried et al.,
(2010) [50]
Randomized
placebo control
trial
Hypertensives 12 weeks 960mg AGE 25/25 SBP—10.2 ± 4.3mmHg dec
Ried et al.,
(2013) [53]
Double-blind,
randomized
placebo-controlled,
dose-response trial
Hypertensives 12 weeks Aged garlic240/480/960mg 26/26/27
SBP—11.8 ± 5.4mmHg, (2
capsule) 7.4 ± 4.1mmHg (4
capsule)
T. chol: total cholesterol, HDL: high density lipoprotein, TG: triglyceride, LDL: low-density lipoprotein, VLDL: very low-density lipoprotein, 8-OHdG: (8-
Hydroxy-2󸀠-deoxyguanosine), and 8-iso-PGF2alpha: (8-iso-Prostaglandin F2alpha).
a period of 12 weeks using 5.6 mg/tablet garlic tablets showed
no significant improvement in lipids levels [37].
An RCT in which 900mg garlic in the form of tablets
(Kwai) was given daily to patients with hypercholesterolemia
showed no significant change in lipid levels in comparison
to placebo group [38]. Similarly, in other trial steams distilled
garlic oil in a quantity of 5mg twice daily for 12 weeks showed
no influence on lipid levels [39]. A trial with garlic usage in
the form of dried form in a dose of 600mg to 1500mg did
not show any effects suggesting that dried preparation in the
dosage studied were ineffective in reducing lipid levels [40].
Similarly, a meta-analyses by Khoo and Aziz also showed
insignificant outcomes [41].
One trial of garlic extract treatment in children with
hypercholesterolemia found no adverse effects and no signif-
icant beneficial effect on lipid levels [42].
Clinical investigations exploring the effects of garlic
and its various preparations in hypercholesterolemia have
demonstrated somewhat contradictory results. The diverse
composition and amount of active sulfur compounds of
different garlic preparations used in various trials might be
responsible for the above mentioned inconsistent findings.
Other factors like subject recruitment, duration of study,
dietary control, lifestyle, and methods of lipid analyses may
also have an influence.These findings emphasize the need for
standardization of garlic preparations in order to reach to a
valid conclusion.
12. Effects of Garlic on Hypertension
Hypertension is an important risk factor for leading to
cardiovascular disease. Currently, it affects 1 billion people
worldwide, and this number is expected to rise to 1.6 billion
by 2025 [43, 44]. Garlic regular consumption has shown
some association with blood pressure control. Blood pressure
reducing properties of garlic are related with the hydrogen
sulphide production [45] and allicin content liberated from
alliin and the enzyme alliinase [46] which is assumed to pos-
sess angiotensin II inhibiting and vasodilating effects. Garlic
is used as a treatment remedy by many people worldwide
to control blood pressure. According to one survey, approxi-
mately 29% of people are using garlic for their blood pressure
control [47].
The antihypertensive effects of garlic have been studied,
but the remaining controversial various studies done showed
controversial results as evident from Table 2. Clinical trial
done by Zhang et al. consuming garlic oil in hypertensive
patients over the 16-week period showed significant results
[48]. A trial using garlic pearls containing 250mg of garlic
among hypertensive patients for 2 months demonstrated
decrease in blood pressure level and also showed decrease in
biomarkers responsible for oxidative stress in blood (plasma-
oxidized LDL, plasma, and urinary concentration of 8-iso-
Prostaglandin F2alpha) ultimately decreasing the risk of
cardiovascular disease [49].
Majority of patients used garlic as a remedy for prevention
from dyslipidemia and hypertension various illnesses. An
RCT conducted by Ried et al. on patients with uncontrolled
blood pressure used AGE preparation of 900mg garlic con-
taining (2.4mg salicystine) for 12 weeks and concluded that
significant reduction in blood pressure level was noted only
among patients who had blood pressure values of more than
140mmHg at baseline [50] suggesting that its role in primary
prevention is questionable.
Another trial by Duda et al. assessed the role of garlic on
blood pressure and lipids levels and concluded that garlic can
be used as a tentative treatment along with antihypertensive
drug because of its positive effect on lipid levels and antioxi-
dant properties [51].
Few meta-analyses were also done to see the efficacy.
In 1994, a meta-analyses assessed the effect of garlic on
hypertension, among which three trials showed significant
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Table 3: Effect of garlic on cardiovascular disease.
Study Type Target Duration oftreatment Dose Route Case/control Outcome
Bordia et al.,
(1998) [63]
Placebo control
trial
Coronary artery
disease patients 3 months
1 gm garlic
(capsules) Oral 30/30
Dec T. chol and TG,
increase HDL level, and
no effect on fibrinogen
and glucose level
Sobenin et al.,
(2010) [71]
Randomized
control trial
Coronary artery
disease patients 1 year
Time-released
garlic powder Oral 26/25
Dec LDL—32.9mg/dL
in males, 27.3mg/dL in
females
T. chol: total cholesterol, HDL: high-density lipoprotein, TG triglyceride, LDL: low-density lipoprotein.
reductions in systolic blood pressure (7.7mmHg greater
reduction), and four trials showed reductions in diastolic
blood pressure (5mmHg greater reduction) in comparison
to placebo [52].
A meta-analyses conducted by Ried et al. showed signifi-
cant results with decrease in systolic blood pressure of about
16.3mmHg and diastolic blood pressure of about 9.3mmHg
in comparison to placebo group; however, these effects were
only observed in patient having systolic blood pressure values
more than 140mmHg [53].
Another meta-analyses done concluded that garlic
reduces mean supine systolic and diastolic blood pressure by
approximately 10–12mmHg and 6–9mmHg, respectively,
over and above the effect of placebo, but the confidence inter-
vals for these effect estimates are not clear cut, and this differ-
ence in blood pressure reduction may be due to subjective
variation in blood pressure measurements suggesting more
clinical trials [54].
Few trials done by Capraz et al. and Pittler and Ernst
showed insignificant results [55, 56]. Similarly a meta-ana-
lyses done by Simons et al. also showed insignificant results
with no effects on blood pressure levels and concluded that
the effect of garlic on blood pressure cannot be established
[57].
To ascertain the effectiveness of garlic in blood pressure
reduction, very few studies are available which have shown
small positive effects, insufficient to draw any conclusions.
Information gathered from the previousmeta-analyses is also
inconclusive due tomethodological shortcomings.Therefore,
in our view, use of garlic cannot be recommended as antihy-
pertensive advice for hypertensive patients in daily practice.
Further, meta-analyses are required to prove its efficacy.
13. Effects on Platelets and
Fibrinolytic Activity
Garlic has a beneficial effect on platelet adhesion or aggre-
gation, a potential risk factor for cardiovascular disease. The
self-condensation products of allicin and ajeones are said to
have antithrombotic action, in addition to its potential effect
in the inhibition of platelet aggregation [58] 23. Dissolution
of clots and thrombi through fibrinolysis is also improved by
garlic.
A number of trials have been conducted to find out the
usefulness of garlic or its preparation against platelets. A
trial by Rahman and Billington reported that garlic causes
inhibition of platelet aggregation by various mechanisms
including inhibition of cyclooxygenase activity leading to
thromboxane A2 formation, by suppressing mobilization
of calcium into the platelets, and by increasing levels of
messengers (cAMP and cGMP) with in the platelets. It also
exhibits strong antioxidant property by increasing produc-
tion of platelet-derived NO. Simultaneously, it also reduces
the ability of platelets to bind to fibrinogen, thus overall
resulting in inhibition of platelet aggregations and enhance
fibrinolytic activity [59].
This fact was further confirmed by a trial by Allison et al.
which showed that AGE extract modified raw preparation of
garlic-inhibited platelet aggregation by suppressing the influx
of calcium ions through their chelationwithin platelet cytosol
or by altering other intracellular second messengers within
the platelets [60].
A trial using AGE preparation of garlic recommended
dose-dependent inhibition of platelet aggregation, that is,
AGE inhibited platelet aggregation at dose of 7.2 gm however
fibrinolytic activity was inhibited at all doses among hyperc-
holesterolemia patients [61]. A trial on ischemic heart disease
patients after using raw/fried garlic significantly increased
fibrinolytic activity [62].
A study using garlic oil as an ingredient reported two
important paraffinic polysulphides diallyl disulphide (DADS)
and diallyl trisulphide (DATS)mainly responsible for causing
antiplatelet inhibition. Action of DATS was found more
potent as compared to DADS; however, it was seen that
inhibition of platelet by DATS was reversible. The results of
this trial conclude that garlic oil should not be used in patients
with comorbid demanding necessary inhibition of platelets
activity [63].
When discussing its efficacy in comparison to statins, its
action was found comparable to compar to clopidogrel [64].
Similarly, it was also suggested that AGE preparation if taken
as a dietary supplement by healthy individuals may be bene-
ficial in protection against cardiovascular disease through
inhibition of platelet aggregation [65].
All of the above results showed some beneficial effects;
however, two studies done by [66] Legnani et al. and [67]
Scharbert et al. on healthy individuals showed no effect on
fibrinolysis and platelet activity.
It is concluded that garlic inhibits platelet aggregation
by multiple mechanisms and may have a role in preventing
cardiovascular disease. However, data is scarce, and further
studies are required to prove this fact.
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14. Garlic Role on Endothelium and
Vascular Dilatation
Though garlic mainly protect against cardiovascular disease
through reduction of lipid levels, however few studies sug-
gest that it has some effects on endothelium and vascular
dilatation through inhibition of oxidation process. Garlic
contains allicin as themain active ingredient with prospect to
provide beneficial effects on cardiovascular system. A study
by Chan et al. [68] showed that allicin caused enhancement
of antioxidant state by lowering of reactive oxygen species
and increasing the production of glutathione. Similarly, garlic
prevents from cardiovascular disease through inhibition of
LDL oxidation thus inhibiting atherosclerosis of vessels,
important risk factors for cardiovascular disease [69]. Budoff
in 2006 conducted a pilot study in which patients who were
already on statin therapywere givenAGE extract of garlic and
placebo and their degree of coronary artery calcification was
assessedwhich slowed down in patient whowere givenGarlic
therapy plus statin as compared to the other group [70].
Garlic role in primary and secondary prevention of car-
diac disease was also questionable as few trials done showed
positive results as demonstrated by Table 3. This fact was
tested among patients with cardiovascular disease by giving
garlic powder tablets allicor, and their 10-year prognostic
risk of acute myocardial infarction and sudden death were
assessed. It was seen that after 12-month treatment with
allicor, there was significant decrease of cardiovascular risk.
that is, 1.5 fold in men and 1.3 fold in women.Themain influ-
ence that played a role in cardiovascular risk reduction was
the decrease in LDL cholesterol by 32.9mg/dL in men and by
27.3mg/dL in women, thus proving the fact that it has effec-
tive role in secondary cardiovascular disease prevention [71].
15. Side Effects of Garlic
A couple of case reports have published the adverse effects
of garlic ingestion, where one claimed allergic dermatitis
observed in a patient taking raw garlic [72]. Another stated
that the antithrombotic activity of garlic might interact with
oral anticoagulants; therefore, caution must be taken when
using in concordance with oral anticoagulants [73].
16. Conclusion
We conclude that the beneficial effect of garlic preparations
on lipids and blood pressure extends also to platelet function,
thus providing a wider potential protection of the cardiovas-
cular system through itsmajor effects on cholestrol reduction.
However, its efficacy in blood pressure reduction is mild
with some beneficial effects on platelet aggregation. This
warrants the need formoremeta-analyses using standardized
preparations with a close watch onmethodological shortfalls.
Disclosure
The authors have no relationships with pharmaceutical com-
panies or products to disclose, and they do not discuss off-
label or investigative products in this paper.
References
[1] B. J. Gersh, K. Sliwa, B. M. Mayosi, and S. Yusuf, “Novel
therapeutic concepts: the epidemic of cardiovascular disease
in the developing world: global implications,” European Heart
Journal, vol. 31, no. 6, pp. 642–648, 2010.
[2] Cardiovascular diseases (CVDs) key facts, 2013, http://www
.who.int/cardiovascular diseases/en/.
[3] World Health Organization, “Cardiovascular diseases,” 2013,
http://www.euro.who.int/en/what-we-do/health-topics/non-
communicable-diseases/cardiovascular-diseases/definition.
[4] D. S. Celermajer, C. K. Chow, E. Marijon, N. M. Anstey, and
K. S. Woo, “Cardiovascular disease in the developing world
prevalence’s, patterns, and the potential of early disease detec-
tion,” Journal of the American College of Cardiology, vol. 60, no.
14, pp. 1207–1216, 2012.
[5] World Health Organization, “Cardiovascular diseases fact
sheet,” 2012, http://www.who.int/mediacentre/factsheets/fs317/
en/index.html.
[6] W. Qidwai, S. R. Alim, R. H. Dhanani, S. Jehangir, A. Nasrullah,
and A. Raza, “Use of folk remedies among patients in Karachi
Pakistan,” Journal of Ayub Medical College, Abbottabad, vol. 15,
no. 2, pp. 31–33, 2003.
[7] M. Frass, R. P. Strassl, H. Friehs, M. Mu¨llner, M. Kundi, and A.
D. Kaye, “Use and acceptance of complementary and alternative
medicine among the general population andmedical personnel:
a systematic review,”The Ochsner Journal, vol. 12, no. 1, pp. 45–
56, 2012.
[8] E. Ernst, “Complementary medicine: common misconcep-
tions,” Journal of the Royal Society of Medicine, vol. 88, no. 5,
pp. 244–247, 1995.
[9] P. M. Barnes, B. Bloom, and R. L. Nahin, “Complementary and
alternative medicine use among adults and children: United
States, 2007,” National Health Statistics Reports, no. 12, pp. 1–23,
2009.
[10] A. F. Omeish, W. Abbadi, I. M. Ghanma et al., “Hospital-based
study on the use of herbal medicine in patients with coro-
nary artery disease in Jordan,” Journal of the Pakistan Medical
Association, vol. 61, no. 7, pp. 683–687, 2011.
[11] R. Rivlin, “Historical perspective on the use of garlic,” Journal of
Nutrition, vol. 131, no. 3, pp. 951S–954S, 2001.
[12] H. P. Koch andL.D. Lawson,Garlic:The Science andTherapeutic
Application of Allium Sativum L. and Related Species, Williams
&Wilkins, Baltimore, Md, USA, 2nd edition, 1996.
[13] M. Steiner and W. Li, “Aged garlic extract, a modulator of
cardiovascular risk factors: a dose-finding study on the effects
of AGE on platelet functions,” Journal of Nutrition, vol. 131, no.
3, pp. 980S–984S, 2001.
[14] L. D. Lawson, “Garlic: a review of its medicinal effects and
indicated active compounds,” in Phytomedicines of Europe:
Chemistry and Biological Activity, L. D. Lawson and R. Bauer,
Eds., vol. 691 of ACS Symposium Series, pp. 176–209, American
Chemical Society, Washington, DC, USA, 1998.
[15] C. Borek, “Antioxidant health effects of aged garlic extract,”
Journal of Nutrition, vol. 131, no. 3, pp. 1010S–1015S, 2001.
[16] E. Block, “The chemistry of garlic and onions,” Scientific Ameri-
can, vol. 252, no. 3, pp. 114–119, 1985.
[17] X. Yan, Z.Wang, and P. Barlow, “Quantitative estimation of gar-
lic oil content in garlic oil based health products,” Food Chem-
istry, vol. 45, no. 2, pp. 135–139, 1992.
8 Evidence-Based Complementary and Alternative Medicine
[18] B. Iberl, G. Winkler, B. Muller, and K. Knobloch, “Quantitative
determination of allicin and alliin from garlic by HPLC,” Planta
Medica, vol. 56, no. 3, pp. 320–326, 1990.
[19] R. Bakhsh and M. I. Chughtai, “Influence of garlic on serum
cholesterol, serum triglycerides, serum total lipids and serum
glucose in human subjects,”Die Nahrung, vol. 28, no. 2, pp. 159–
163, 1984.
[20] F. H.Mader, “Treatment of hyperlipidaemia with garlic-powder
tablets. Evidence from the German association of general prac-
titioners’ multicentric placebo-controlled double-blind study,”
Arzneimittel-Forschung, vol. 40, no. 10, pp. 1111–1116, 1990.
[21] R. C. Arora, S. Arora, and R. K. Gupta, “The long-term use of
garlic in ischemic heart disease. An appraisal,” Atherosclerosis,
vol. 40, no. 2, pp. 175–179, 1981.
[22] Y. S. K. Khoo and Z. Aziz, “Garlic supplementation and serum
cholesterol: a meta-analysis,” Journal of Clinical Pharmacy and
Therapeutics, vol. 34, no. 2, pp. 133–145, 2009.
[23] P. S. Yusuf, S. Hawken, S. Oˆunpuu et al., “Effect of potentially
modifiable risk factors associated with myocardial infarction
in 52 countries (the INTERHEART study): case-control study,”
The Lancet, vol. 364, no. 9438, pp. 937–952, 2004.
[24] V. K. Singh and D. K. Singh, “Pharmacological effects of garlic
(Allium sativum L.),” Annual Review of Biomedical Sciences, vol.
10, pp. 6–26, 2008.
[25] H. Sumiyoshi, “New pharmacological activities of garlic and its
constituents,” Folia Pharmacologica Japonica, vol. 110, supple-
ment 1, pp. 93P–97P, 1997.
[26] T. Saradeth, S. Seidl, K. L. Resch, and E. Ernst, “Does garlic alter
the lipid pattern in normal volunteers?” Phytomedicine, vol. 1,
no. 3, pp. 183–185, 1994.
[27] J. V. Gadkari and V. D. Joshi, “Effect of ingestion of raw garlic on
serum cholesterol level, clotting time and fibrinolytic activity in
normal subjects,” Journal of Postgraduate Medicine, vol. 37, no.
3, pp. 128–131, 1991.
[28] I. A. Sobenin, I. V. Andrianova, O. N. Demidova, T. V. Gor-
chakova, and A. N. Orekhov, “Lipid-lowering effects of time-
released garlic powder tablets in double-blinded placebo-con-
trolled randomized study,” Journal of Atherosclerosis andThrom-
bosis, vol. 15, no. 6, pp. 334–338, 2008.
[29] M. Steiner, A. H. Khan, D. Holbert, and R. I. S. Lin, “A double-
blind crossover study in moderately hypercholesterolemic men
that compared the effect of aged garlic extract and placebo
administration on blood lipids,”The American Journal of Clini-
cal Nutrition, vol. 64, no. 6, pp. 866–870, 1996.
[30] M. Mahmoodi, M. R. Islami, G. R. A. Karam et al., “Study of
the effects of raw garlic consumption on the level of lipids and
other blood biochemical factors in hyperlipidemic individuals,”
Pakistan Journal of Pharmaceutical Sciences, vol. 19, no. 4, pp.
295–298, 2006.
[31] W. Rotzsch, V. Richter, F. Rassoul, and A. Walper, “Postpran-
dial lipaemia under treatment with Allium sativum/controlled
double-blind study in healthy volunteers with reduced HDL2-
cholesterol levels,” Arzneimittel-Forschung, vol. 42, no. 10, pp.
1223–1227, 1992.
[32] M. Ali and M. Thomson, “Consumption of a garlic clove a day
could be beneficial in preventing thrombosis,” Prostaglandins
Leukotrienes and Essential Fatty Acids, vol. 53, no. 3, pp. 211–212,
1995.
[33] C. Silagy and A. Neil, “Garlic as a lipid lowering agent—ameta-
analysis,” Journal of the Royal College of Physicians of London,
vol. 28, no. 1, pp. 39–45, 1994.
[34] S. Warshafsky, R. S. Kamer, and S. L. Sivak, “Effect of garlic
on total serum cholesterol: a meta-analysis,” Annals of Internal
Medicine, vol. 119, no. 7, pp. 599–605, 1993.
[35] T. Zeng, F. F. Guo, C. L. Zhang, F. Y. Song, X. L. Zhao, and K.
Q. Xie, “Ameta-analysis of randomized, double-blind, placebo-
controlled trials for the effects of garlic on serum lipid profiles,”
Journal of the Science of Food and Agriculture, vol. 92, no. 9, pp.
1892–1902, 2012.
[36] H. Holzgartner, U. Schmidt, and U. Kuhn, “Comparison of the
efficacy and tolerance of a garlic preparation versus bezafibrate,”
Arzneimittel-Forschung, vol. 42, no. 12, pp. 1473–1477, 1992.
[37] P. Satitvipawee, P. Rawdaree, S. Indrabhakti, T. Ratanasuwan, P.
Getn-gern, and C. Viwatwongkasem, “No effect of garlic extract
supplement on serum lipid levels in hypercholesterolemic
subjects,” Journal of Medical Association, vol. 86, no. 8, pp. 750–
757, 2003.
[38] J. L. Isaacsohn, M. Moser, E. A. Stein et al., “Garlic powder
and plasma lipids and lipoproteins: a multicenter, randomized,
placebo-controlled trial,” Archives of Internal Medicine, vol. 158,
no. 11, pp. 1189–1194, 1998.
[39] H. K. Berthold, T. Sudhop, and K. von Bergmann, “Effect of
a garlic oil preparation on serum lipoproteins and cholesterol
metabolism: a randomized controlled trial,” The Journal of the
American Medical Association, vol. 279, no. 23, pp. 1900–1902,
1998.
[40] C. Luley, W. Lehmann-Leo, and B. Moller, “Lack of efficacy
of dried garlic in patients with hyperlipoproteinemia,” Arznei-
mittel-Forschung, vol. 36, no. 4, pp. 766–768, 1986.
[41] Y. S. K. Khoo and Z. Aziz, “Garlic supplementation and serum
cholesterol: a meta-analysis,” Journal of Clinical Pharmacy and
Therapeutics, vol. 34, no. 2, pp. 133–145, 2009.
[42] B. W. McCrindle, E. Helden, and W. T. Conner, “Garlic extract
therapy in children with hypercholesterolemia,” Archives of
Pediatrics and Adolescent Medicine, vol. 152, no. 11, pp. 1089–
1094, 1998.
[43] The Seventh Report of the Joint National Committee on Preven-
tion, Detection, Evaluation, and Treatment of High Blood Pres-
sure, NIH publication 03-5233, National Institutes of Health:
National Heart, Lung, and Blood Institute, National High Blood
Pressure Education Program, Bethesda, Md, USA, 2003.
[44] P. M. Kearney, M. Whelton, K. Reynolds, P. Muntner, P. K.
Whelton, and J. He, “Global burden of hypertension: analysis
of worldwide data,”The Lancet, vol. 365, no. 9455, pp. 217–223,
2005.
[45] G. A. Benavides, G. L. Squadrito, R. W. Mills et al., “Hydrogen
sulfide mediates the vasoactivity of garlic,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 104, no. 46, pp. 17977–17982, 2007.
[46] S. K. Banerjee, P. K. Mukherjee, and S. K. Maulik, “Garlic as an
antioxidant: the good, the bad and the ugly,” Phytotherapy Re-
search, vol. 17, no. 2, pp. 97–106, 2003.
[47] P. E. Osamor and B. E. Owumi, “Complementary and alterna-
tive medicine in the management of hypertension in an urban
Nigerian community,” BMC Complementary and Alternative
Medicine, vol. 10, article 36, 2010.
[48] X. H. Zhang, D. Lowe, P. Giles et al., “A randomized trial of the
effects of garlic oil upon coronary heart disease risk factors in
trained male runners,” Blood Coagulation and Fibrinolysis, vol.
12, no. 1, pp. 67–74, 2001.
[49] V. Dhawan and S. Jain, “Effect of garlic supplementation on
oxidized low density lipoproteins and lipid peroxidation in
Evidence-Based Complementary and Alternative Medicine 9
patients of essential hypertension,”Molecular and Cellular Bio-
chemistry, vol. 266, no. 1-2, pp. 109–115, 2004.
[50] K. Ried, O. R. Frank, and N. P. Stocks, “Aged garlic extract
lowers blood pressure in patients with treated but uncontrolled
hypertension: a randomised controlled trial,”Maturitas, vol. 67,
no. 2, pp. 144–150, 2010.
[51] G. Duda, J. Suliburska, and D. Pupek-Musialik, “Effects of
short-term garlic supplementation on lipid metabolism and
antioxidant status in hypertensive adults,” Pharmacological
Reports, vol. 60, no. 2, pp. 163–170, 2008.
[52] C. A. Silagy and H. A. W. Neil, “A meta-analysis of the effect of
garlic on blood pressure,” Journal of Hypertension, vol. 12, no. 4,
pp. 463–468, 1994.
[53] K. Ried, O. R. Frank, and N. P. Stocks, “Aged garlic extract
reduces blood pressure in hypertensives: a dose-response trial,”
European Journal of Clinical Nutrition, vol. 67, no. 1, pp. 64–70,
2013.
[54] S. N. Stabler, A. M. Tejani, F. Huynh, and C. Fowkes, “Garlic
for the prevention of cardiovascular morbidity and mortality
in hypertensive patients,” Cochrane Database of Systematic
Reviews, no. 8, Article ID CD007653, 2009.
[55] M. Capraz, M. Dilek, and T. Akpolat, “Garlic, hypertension and
patient education,” International Journal of Cardiology, vol. 121,
no. 1, pp. 130–131, 2007.
[56] M. H. Pittler and E. Ernst, “Clinical effectiveness of garlic
(Allium sativum),” Molecular Nutrition and Food Research, vol.
51, no. 11, pp. 1382–1385, 2007.
[57] S. Simons, H. Wollersheim, and T. Thien, “A systematic review
on the influence of trial quality on the effect of garlic on blood
pressure,”Netherlands Journal ofMedicine, vol. 67, no. 6, pp. 212–
219, 2009.
[58] K. Teranishi, R. Apitz-Castro, S. C. Robson, E. Romano, and D.
K. C. Cooper, “Inhibition of baboon platelet aggregation in vitro
and in vivo by the garlic derivative, ajoene,” Xenotransplanta-
tion, vol. 10, no. 4, pp. 374–379, 2003.
[59] K. Rahman and D. Billington, “Dietary supplementation with
aged garlic extract inhibits ADP-induced platelet aggregation in
humans,” Journal of Nutrition, vol. 130, no. 11, pp. 2662–2665,
2000.
[60] G. L. Allison, G. M. Lowe, and K. Rahman, “Aged garlic extract
may inhibit aggregation in human platelets by suppressing
calcium mobilization,” Journal of Nutrition, vol. 136, no. 3, pp.
789S–792S, 2006.
[61] M. Steiner andW. Li, “Aged garlic extract, a modulator of card-
iovascular risk factors: a dose-finding study on the effects of
AGE on platelet functions,” Journal of Nutrition, vol. 131, no. 3,
pp. 980S–984S, 2001.
[62] S. K.Chutani andA. Bordia, “The effect of fried versus raw garlic
on fibrinolytic activity in man,” Atherosclerosis, vol. 38, no. 3-4,
pp. 417–421, 1981.
[63] A. Bordia, S. K. Verma, and K. C. Srivastava, “Effect of garlic
(Allium sativum) on blood lipids, blood sugar, fibrinogen and
fibrinolytic activity in patients with coronary artery disease,”
Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 58,
no. 4, pp. 257–263, 1998.
[64] B. Hiyasat, D. Sabha, K. Gro¨tzinger et al., “Antiplatelet activity
of Allium ursinum and Allium sativum,” Pharmacology, vol. 83,
no. 4, pp. 197–204, 2009.
[65] K. Rahman, “Effects of garlic on platelet biochemistry and phy-
siology,” Molecular Nutrition and Food Research, vol. 51, no. 11,
pp. 1335–1344, 2007.
[66] C. Legnani, M. Frascaro, G. Guazzaloca, S. Ludovici, G.
Cesarano, and S. Coccheri, “Effects of a dried garlic preparation
on fibrinolysis and platelet aggregation in healthy subjects,”Arz-
neimittel-Forschung, vol. 43, no. 2, pp. 119–122, 1993.
[67] G. Scharbert, M. L. Kalb, M. Duris, C. Marschalek, and S. A.
Kozek-Langenecker, “Garlic at dietary doses does not impair
platelet function,” Anesthesia and Analgesia, vol. 105, no. 5, pp.
1214–1218, 2007.
[68] J. Y. Chan, A. C. Yuen, R. Y. Chan, and S. W. Chan, “A review
of the cardiovascular benefits and antioxidant properties of alli-
cin,” Phytotherapy Research, 2012.
[69] B. H. S. Lau, “Suppression of LDL oxidation by garlic,” Journal
of Nutrition, vol. 131, no. 3, pp. 985S–988S, 2001.
[70] M. Budoff, “Aged garlic extract retards progression of coronary
artery calcification,” Journal of Nutrition, vol. 136, no. 3, supple-
ment, pp. 741S–744S, 2006.
[71] I. A. Sobenin, V. V. Pryanishnikov, L. M. Kunnova, Y. A. Rabi-
novich, D. M. Martirosyan, and A. N. Orekhov, “The effects of
time-released garlic powder tablets on multifunctional cardio-
vascular risk in patients with coronary artery disease,” Lipids in
Health and Disease, vol. 9, article 119, 2010.
[72] S. Ma and J. Yin, “Anaphylaxis induced by ingestion of raw
garlic,” Foodborne Pathogens and Disease, vol. 9, no. 8, pp. 773–
775, 2012.
[73] K. D. Rose, P. D. Croissant, C. F. Parliament, and M. B. Levin,
“Spontaneous spinal epidural hematoma with associated plate-
let dysfunction from excessive garlic ingestion: a case report,”
Neurosurgery, vol. 26, no. 5, pp. 880–882, 1990.
